GlassScriptPhysician profile
Stephanie Maniaci
NPI 1114302130
$1,085.62
in general payments reported to CMS, 2019-2025
14 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.46 · 2022: $74.38 · 2023: $190 · 2024: $545 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $542 · Travel and Lodging: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $542.07 |
| Travel and Lodging | $411.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $411.71 | 2024 | Cardiomems |
| Lilly USA, LLC | $105.17 | 2021-2025 | Mounjaro |
| Amgen INC. | $93.92 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $88.58 | 2021-2024 | |
| Novo Nordisk INC | $81.75 | 2023 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $74.28 | 2021-2025 | Veozah |
| Glaxosmithkline, LLC. | $67.36 | 2023-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $47.02 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.90 | 2024 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $24.14 | 2025 | Breztri |
| Otsuka America Pharmaceutical, INC. | $17.66 | 2023 | Nuedexta, Rexulti |
| Collegium Pharmaceutical, INC. | $16.59 | 2024 | Xtampza |
| Janssen Pharmaceuticals, INC | $16.45 | 2022 | |
| Lundbeck LLC | $16.09 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Maniaci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.